US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
pharma · Osteoarthritis · Pain
Mundipharma
Mundipharma Pty Limited
Mundipharma drug portfolio — 23 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Sydney, AU HQ
1952 Founded
2,082 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Sydney, AU
- Founded
- 1952
- Employees
- 2,082
- Programs
- 4
- Drugs
- 23
- Patents
- 0
Mundipharma pipeline
Portfolio lens on 23 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Mundipharma drug portfolio — 23 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
buprenorphine
Nervous system (N07)US regulatory status: approved. Molecular target: Kappa-type opioid receptor.
- Target
- Kappa-type opioid receptor
- Mechanism
- Kappa opioid receptor agonist
-
Development asset linked to Mundipharma in public FDA and regional records.
-
Development asset linked to Mundipharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
Development asset linked to Mundipharma in public FDA and regional records.
-
Development asset linked to Mundipharma in public FDA and regional records.
-
Development asset linked to Mundipharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to Mundipharma in public FDA and regional records.
-
posaconazole
Antiinfectives for systemic use (J02)US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
Development asset linked to Mundipharma in public FDA and regional records.
-
pralatrexate
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
rezafungin
Antiinfectives for systemic use (J02)Antiinfectives for systemic use (J02) compound in Mundipharma's portfolio.
-
US regulatory status: approved. Molecular target: Candida.
- Target
- Candida
- Mechanism
- Candida inhibitor
-
Development asset linked to Mundipharma in public FDA and regional records.
-
Development asset linked to Mundipharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Dihydropteroate synthase.
- Target
- Dihydropteroate synthase
- Mechanism
- Bacterial dihydropteroate synthase inhibitor
-
Development asset linked to Mundipharma in public FDA and regional records.
-
Development asset linked to Mundipharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.
- Target
- Beta-1 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor antagonist
-
Development asset linked to Mundipharma in public FDA and regional records.